. 2022 Dec 15;10(1):ofac673. doi: 10.1093/ofid/ofac673

Table 2.

Data From HPTN 083/084 Trials on Infection Rate by Treatment Arm, Extrapolated Across to Give Risk Reduction on Cabotegravir vs TDF/FTC, and Number Needed to Treat to Cause Benefit as a Result

	Infection Rate, No. (%)		Risk Reduction, %	NNTB
Trial	TDF/FTC	Cabotegravir	Risk Reduction, %	NNTB
HPTN 083	39/3187 (1.22)	13/3205 (0.41)	0.81	124
HPTN 084	56/1610 (3.48)	6/1613 (0.37)	3.11	33
Both	95/4797 (1.98)	19/4818 (0.39)	1.59	63

Abbreviations: NNTB, number needed to treat to cause benefit (prevention of 1 infection), calculated by 100 divided by risk reduction; TDF/FTC, tenofovir/emtricitabine.